Streetbeat News

Regulatory

VERA

Vera Therapeutics shares are trading higher after the company received FDA Breakthrough Therapy Designation for Atacicept.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 1:18 pm

FLUT

Flutter Entertainment shares are trading lower after the Illinois Senate approved a 2025 budget that includes a sports betting tax hike.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 1:14 pm

DKNG

DraftKings Inc (NASDAQ:DKNG) shares are trading lower after the Illinois Senate approved a 2025 budget that includes a significant sports betting tax hike. The new tax rate would more than double the current rate, potentially impacting DraftKings' profitability in Illinois.

Portfolio Pulse from Adam Eckert

May 28, 2024 | 1:10 pm

BLCO

Bausch + Lomb announced that Health Canada has approved its enVista Envy Full Visual Range Intraocular Lens.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 1:06 pm

INSM

Insmed Incorporated (NASDAQ:INSM) shares surged after the company announced positive topline results from the ASPEN Phase 3 study of brensocatib in patients with non-cystic fibrosis bronchiectasis. The study met its primary and several secondary endpoints, showing significant reductions in pulmonary exacerbations. Insmed plans to file a New Drug Application with the FDA in Q4 2024, with a potential U.S. launch in mid-2025.

Portfolio Pulse from Vandana Singh

May 28, 2024 | 12:58 pm

SINT

Trading halt status for SINT was updated at 8:55:00 AM ET. The quotation resumption times and related news are expected to follow.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:55 pm

ABTC

BTCUSD

BTCW

CBTC

The first Bitcoin exchange-traded products (ETPs) have started trading on the London Stock Exchange, marking a significant milestone for cryptocurrency adoption in the U.K. Asset managers WisdomTree and 21Shares listed Bitcoin ETPs, including 21Shares Bitcoin ETN (ABTC), 21Shares Bitcoin Core ETN (CBTC), and WisdomTree Physical Bitcoin ETN (BTCW). These products are currently accessible only to professional investors under FCA regulations.

Portfolio Pulse from Benzinga Neuro

May 28, 2024 | 12:51 pm

APRE

Aprea Therapeutics' Safety Review Committee has endorsed dosing patients with ATRN-119 in the ABOYA-119 clinical trial. ATRN-119, a macrocyclic ATR inhibitor, has shown safety and tolerance through the first 5 cohorts with no dose-limiting toxicities. The company is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:48 pm

PTCT

PTC Therapeutics announced that the European Medicines Agency (EMA) has validated and accepted the marketing authorization application (MAA) for sepiapterin, a treatment for phenylketonuria (PKU).

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:45 pm

CATC

EBC

Eastern Bankshares, Inc. (EBC) and Cambridge Bancorp (CATC) have received all necessary regulatory approvals for their proposed merger, expected to close on or about July 12, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:44 pm